NVIDIA Sets Conference Call for First-Quarter Financial Results CFO Commentary to Be Provided in Writing Ahead of Call SANTA CLARA, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- NVIDIA will host a conference call on Wednesday, May 22, at 2 p.m. PT (5 p.m. ET) to discuss its financial results for the first quarter of fiscal year 2025, which ended April 28, 2024. The call will be webcast live (in listen-only mode) on . The company’s prepared remarks will be followed by a question-and-answer session, which will be limited to questions from financial analysts and institutional investors. Ahead...
Ansys Announces Q1 Financial Results / Q1 2024 Results Revenue of $466.6 millionGAAP diluted earnings per share of $0.40 and non-GAAP diluted earnings per share of $1.39GAAP operating profit margin of 9.3% and non-GAAP operating profit margin of 32.2%Operating cash flows of $282.8 million and unlevered operating cash flows of $292.7 millionAnnual Contract Value (ACV) of $407.4 millionDeferred revenue and backlog of $1,369.5 million on March 31, 2024 PITTSBURGH, May 01, 2024 (GLOBE NEWSWIRE) -- ANSYS, Inc. (NASDAQ: ANSS), today reported first quarter 2024 revenue of $466.6 million, a ...
Devon Energy Reports First-Quarter 2024 Results and Declares Quarterly Dividend OKLAHOMA CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Devon Energy Corp. (NYSE: DVN) today reported financial and operational results for the first-quarter 2024. The company also declared its quarterly dividend and provided an updated outlook for 2024. Devon’s earnings release, supplemental financial tables, guidance and related earnings presentation can be accessed via the section of Devon’s website, . The company’s first-quarter conference call will be held at 10:00 a.m. Central (11:00 a.m. Eastern) on Thursday,...
FormFactor, Inc. Reports 2024 First Quarter Results Reports Q1 Revenue Near the Top-End of the Outlook Range, Sees Significant Step-Up in Demand in Q2’24 LIVERMORE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) today announced its financial results for the first quarter of fiscal 2024 ended March 30, 2024. Quarterly revenues were $168.7 million, an increase of 0.3% compared to $168.2 million in the fourth quarter of fiscal 2023, and an increase of 0.8% from $167.4 million in the first quarter of fiscal 2023. Revenue near the top-end of the outlook range; no...
Micron First to Ship Critical Memory for AI Data Centers Micron reaches industry milestone as first to validate and ship 128GB DDR5 32Gb server DRAM to address the rigorous speed and capacity demands of memory-intensive Gen AI applications BOISE, Idaho, May 01, 2024 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU), today announced it is leading the industry by validating and shipping its high-capacity monolithic 32Gb DRAM die-based in speeds up to 5,600 MT/s on all leading server platforms. Powered by Micron’s industry-leading 1β (1-beta) technology, the 128GB DDR5 RDIMM memory ...
Repligen Reports First Quarter 2024 Financial Results Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidan...
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025 WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 stu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.